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The epigenetic regulator CTCF modulates BCL6 in lymphoma
Ana Batlle-López, María G. Cortiguera and M. Dolores Delgado
Despite the improvements in the diagnosis and in 
the approaches to treatment, aggressive lymphomas are 
still an important cause of morbidity and mortality. There 
is, therefore, considerable interest in understanding the 
mechanisms involved in the process of lymphomagenesis. 
Germinal centers are dynamic structures within the 
lymph nodes containing highly proliferating B-cells 
that are undergoing mutations, in order to produce high 
affinity maturation antibodies, and for these reasons are 
predisposed to the formation of malignancies. Indeed, a 
number of mature lymphoid neoplasms are generated in 
these structures. 
BCL6 is an important transcriptional repressor 
known to be the master regulator of the germinal center, 
required to differentiate follicular B cells into germinal 
center B cells and to maintain these cells in this state [1]. 
BCL6 is highly regulated during B cell differentiation 
such that naïve B-cells and terminally differentiated 
plasma cells do not express the protein whilst germinal 
centre B-cells expresses large amounts. BCL6 deregulated 
expression is sufficient to induce a lymphoproliferative 
disease similar to the human Diffuse large B-cell 
lymphoma in mice. Therefore, is of critical importance 
to understand how the expression of BCL6 is regulated. 
However, many aspects related to the mechanisms 
involved in the regulation of the gene in normal B-cells 
and in lymphomas derived from germinal center B-cell 
still remain unclear. Our recent study sheds light on the 
epigenetic regulation of BCL6 expression by the CTCF 
chromatin regulator [2].
CTCF is a highly conserved, ubiquitously expressed 
zinc finger protein. The functions described for CTCF 
include transcriptional activation or repression, insulator 
binding protein and global organization of chromatin, 
through the facilitation of long-range interactions and 
chromatin looping [3]. CTCF is involved in the regulation 
of various genes implicated in cancer, frequently through 
epigenetic mechanisms. Chromatin structure and 
modifications are considered nowadays critical aspects 
of gene expression regulation. The main epigenetic 
mechanisms are histone modifications as acetylation or 
methylation, and DNA methylation in CpG dinucleotides. 
Gene activation is related with unmethylated DNA near 
the gene promoters and with marks of active chromatin 
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Figure 1: Model for BCL6 regulation by CTCF. CTCF binding to exon1A, associated with active histone marks, impairs BCL6 
negative autoregulation allowing BCL6 expression in germinal center B cells. For differentiation into plasmatic cells, CTCF is released 
from exon1A site allowing BCL6 negative autoregulatory circuit to function. This leads to recruitment of repressive marks, chromatin 
condensation and inhibition of BCL6 expression. In turn, BCL6 downregulation allows BLIMP1 and IRF4 expression, both required for 
plasma cell differentiation. 
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such as histone acetylation or histone methylation in 
specific residues. These modifications confer an open 
chromatin structure at that locus. On the contrary, gene 
repression is related with specific repressive histone marks 
that recruit repressive complexes, giving rise to a close 
conformation of the chromatin and silencing of gene 
expression [4]. 
In our work we show that CTCF binds to a 
previously undescribed site in BCL6 exon1A [2]. Features 
that make CTCF binding to exon 1A a likely mechanism 
to induce BCL6 expression in germinal center cells are: 
i) CTCF binding to this site was associated with high 
levels of BCL6 expression, while lack of CTCF binding 
was correlated with reduction of BCL6 expression in 
germinal center B-cells and induction of plasma cell 
markers; ii) CTCF binding was required to maintain BCL6 
expression in germinal center cells by avoiding the well-
known BCL6 negative autoregulation; iii) CTCF binding 
to BCL6 exon1A was associated with presence of active 
histone marks and protection against repressive marks. 
These findings are summarized in the Figure 1. Notably, 
CTCF has also been associated to negative regulation 
of BCL6 expression upon binding to an unmethylated 
intron 1 in plasma cells [5]. It is, therefore, tempting to 
speculate that BCL6 expression might depend on the 
stage-specific CTCF recruitment to the different BCL6 
binding sites during B lymphocyte development. CTCF 
binding to exon1A appears to be required to maintain 
BCL6 expression by protecting BCL6 exon1A from BCL6 
auto-repression in germinal center cells. On the contrary, 
CTCF binding to the intronic region is more likely to be 
necessary to prevent BCL6 expression in non-germinal 
center cells and allow differentiation.
BCL6 is an attractive target for therapy and indeed 
different specific BCL6 inhibitors are currently under 
investigation. Treatments with drugs that modify the 
chromatin have enormous potential for cancer therapy 
[4]. Epigenetic modulation of BCL6 expression might 
be effective in germinal center derived lymphomas. 
Preliminary results performed in our laboratory showed 
that treatment of germinal center derived B cell lines 
with histone deacetylase inhibitors downregulated BCL6 
expression, caused plasma cell differentiation and induced 
cell death. The possible role of CTCF in this process is 
currently under study. 
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